XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.53
−1.67%Year over year
Reported trailing growth
- Revenue
- +60.7%
- EBITDA
- +16.5%
- EBIT
- +27.3%
- EPS
- +28.6%
- Free cash flow
- +45.5%
- Operating cash flow
- +43.0%
Forward estimates
Based on analyst estimates
- Revenue
- +40.7%
- EBITDA
- +83.3%
- EPS
- +79.8%
Three-year CAGR
- Revenue
- +157.4%
- EBITDA
- +25.4%
- EBIT
- +34.8%
- Net income
- +28.7%
- EPS
- +98.5%
- Free cash flow
- +56.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026